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Abstract
The biologic aggressiveness of prostate tumors is an
important indicator of prognosis. Chromosome 7q32—
q33 was recently reported to show linkage to more
aggressive prostate cancer, based on Gleason score, in
a large sibling pair study. We report confirmation and
narrowing of the linked region using finer -scale
genotyping. We also report a high frequency of allelic
imbalance (AI) defined within this locus in a series of
48 primary prostate tumors from men unselected for
family history or disease status. The highest frequency
of AI was observed with adjacent markers D7S2531
(52%) and D7S1804 (36%). These two markers de-
lineated a common region of AI, with 24 tumors
exhibiting interstitial AI involving one or both markers.
The 1.1-Mb candidate region contains relatively few
transcripts. Additionally, we observed positive associ-
ations between interstitial AI at D7S1804 and early age
at diagnosis (P=.03) as well as a high combined
Gleason score and tumor stage (P=.06). Interstitial AI
at D7S2531 was associated with a positive family
history of prostate cancer (P=.05). These data imply
that we have localized a prostate cancer tumor
aggressiveness loci to chromosome 7q32–q33 that is
involved in familial and nonfamilial forms of prostate
cancer.
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Introduction
Prostate cancer is the most commonly diagnosed neoplasm
and the second leading cause of cancer mortality in men in
the USA, with 30,200 deaths predicted in 2002 [1]. Despite
this, little is known regarding the genetic etiology of this
disease or why some prostate tumors are biologically more
aggressive than others.
Studies to date indicate the presence of multiple prostate
cancer susceptibility loci including: HPC1 located on 1q24–
q25 [2], CAPB on 1p36 [3], PCAP on 1q42.2–q43 [4],
8p22–p23 [5], HPC2 on 17p [6], 16q23–q24 [7], 20q [8]
and HPCX on Xq27–q28 [9]. Whereas there is some
supporting evidence for many of these candidate loci [10–
18], several studies have failed to verify any linkage to these
regions [19–25]. These complex and apparently contra-
dictory linkage data strongly suggest a heterogeneous nature
of hereditary prostate cancer [26]. Four members of our
group (D.V.C., W.J.C., B.K.S. and J.S.W.) have recently
reported the identification of chromosomal regions at 5q31–
q33, 7q32–q33, and 19q12 that exhibit linkage to more
aggressive forms of prostate cancer [27], as determined by
Gleason score [28].
We chose to further examine chromosome 7q32–q33 as
reports indicate frequent deletions of the long arm of
chromosome 7 in prostate cancer [29,30] and many other
tumor types including breast [31], pancreas [32], stomach
[33], thyroid [34], and ovary [35]. Allelic imbalance (AI) of 7q
is also associated with poor outcome in patients with prostate
cancer [36]. Specifically, a significant correlation has been
reported between 7q AI and higher Gleason score, increased
mortality and systemic progression of disease at follow-up
[37], all considered markers of more aggressive disease.
Loss of heterozygosity (LOH) at 7q31 is the most commonly
reported alteration in many tumor types and is often observed
in early -stage cancers [29,34,35]. Recent evidence sug-
gests that ST7 is the tumor suppressor gene associated with
LOH at 7q31 [38].
The present study was designed to further characterize
the candidate prostate tumor aggressiveness locus on
7q32–q33 by utilizing linkage analysis and AI techniques.
In this report, we confirm and narrow the previously reported
linkage region on chromosome 7q32–q33 and report a high
frequency of AI within this region. The current study
provides strong evidence for the presence of a prostate
cancer aggressiveness gene mapping to 7q32–q33 that
may play a role in both familial and nonfamilial forms of
prostate cancer.
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Materials and Methods
Radiation Hybrid Mapping
The order of the 11 microsatellite markers across 7q used
in the AI study was determined using the Genebridge 4
(GB4) low-resolution radiation hybrid panel (Research
Genetics, Huntsville, AL). The GB4 panel [39] contains
DNAs from 93 human fibroblast -derived human:hamster
hybrids. Individual PCR reactions were performed for each
hybrid with each of the 11 markers shown in Table 1. The
PCR reactions were performed using a PCR thermal cycler
(MWG Biotech, Highpoint, NC). Each 15-l reaction
contained 2 l of DNA, 1.25 mM of each deoxynucleotide
triphosphate, 0.5 M reverse primer, 0.5 M forward primer,
0.75 U of Taq DNA polymerase (Life Technologies, Rock-
ville, MD), 67 mM Tris–HCl (pH 8.8), 67 mM magnesium
chloride, 16.6 mM ammonium sulfate, 10 mM  -mercapto-
ethanol, and 10% DMSO. The DNA amplification cycle
comprised a 5-minute denaturation step at 948C, 35 cycles
of 948C for 45 seconds, annealing at the appropriate
temperature for 1 minute, and extension for 1 minute at
728C, followed by a final 5-minute extension at 728C. Ten
microliters of each PCR product was resolved on a 6%
nondenaturing polyacrylamide gel and visualized following
ethidium bromide staining. Each hybrid was scored for the
presence or absence of the PCR product with all 11 markers.
The results were analyzed using the Map Manager QT
program [40] to determine the relative order and distance
between markers (Table 1).
Genotyping Methods
A higher density linkage analysis across the 7q32–q34
region was performed on 513 men, from the equivalent of
326 concordant sibships, from the original sibling pair study
[27]. Five microsatellite markers were chosen; one of
these markers (D7S530) lies distal and the remaining four
(D7S2452, D7S640, D7S684, and D7S495) lie proximal to
the marker exhibiting the highest degree of linkage
(D7S1804) in the previous study [27]. PCR was carried
out for each marker using blood lymphocyte DNA from
each individual in the study. Each forward primer was
designed to include a fluorophore at the 50 end to enable
detection and analysis on an ABI 373 XL DNA sequencer.
Before loading onto a 6% denaturing polyacrylamide gel,
PCR products were diluted in water and multiplexed
according to marker size and fluorophore. One microliter
of multiplexed product was then added to 3 l of formamide
loading dye, containing a 350 base pair 6-carboxytetra-
methylrhodamine size standard (Applied Biosystems,
Foster City, CA) and denatured at 958C for 5 minutes.
ABI Collection and ABI Genescan version 3.1 software
packages (Applied Biosystems) were used to process
each electrophoresis run. Marker allele sizes and intensity
for each sample was assessed using Genotyper software
(Applied Biosystems).
Patient Selection and Evaluation of Tissue
A consecutive series of 51 prostate patients, for whom
we had both tumor tissue and comprehensive clinical data
available, were identified through the tumor registry at the
Cleveland Clinic Foundation. This study was approved by
the Institutional Review Board of the Cleveland Clinic
Foundation. Each tumor was staged at the time of surgery
and graded, using the Gleason system, following assess-
ment of microscopic sections of the surgical specimen.
Normal and tumor tissue from each case was micro-
dissected from 5-m unstained paraffin-embedded tissue
sections, as previously described [16], following the review
and annotation of a corresponding hematoxylin and eosin
stained section by a pathologist (H.L. ). DNA was extracted
from the microdissected tissue using the Qiagen Tissue Kit
(Qiagen, Valencia, CA) and eluted in 100 l of Tris buffer
(pH 9). Final tumor DNA content was estimated to be at
least 70%. Three patients were subsequently removed from
the study due to insufficient DNA quality for PCR
amplification. A total of 48 patients were included in our
genetic analysis. Clinical information for all patients is noted
in Table 2.
AI Study
Eleven microsatellite markers were used in the AI study
(Table 3). Of these, three (D7S3061, D7S1804, and
D7S1824) had shown significant linkage to aggressive
disease in our prostate cancer sibling linkage study [27].
Information regarding primer sequence was obtained from
the Genome Database (http: / /www.gdb.org). Separate
PCR reactions were performed using DNA from micro-
dissected normal and tumor tissue. PCR conditions were as
described above, but using a  -32P end- labeled forward
primer. End- labeling with [ - 32P]dATP was carried out
using T4 polynucleotide kinase (USB, Cleveland, OH). Two
Table 1. Radiation Hybrid Map Order of 11 Microsatellite Markers on 7q.
Marker Intermarker Distance* ( cR -3000 )
D7S3061
34.44
D7S1875
27.44
D7S530
8.06
D7S2519
14.45
D7S2531
30.62
D7S1804
12.68
D7S2452
8.92
D7S640
63.15
D7S684
11.02
D7S495
28.44
D7S1824
*Map distances are based on D7S3061 as 0.
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microliters of PCR product was combined with 4 l of 95%
formamide loading dye containing 20 mM EDTA, 0.5 mg/ml
bromophenol blue, and 0.5 mg/ml xylene cyanol. The
sample mixtures were denatured at 958C for 5 minutes and
immediately cooled on ice before loading onto a 6%
denaturing polyacrylamide gel. Gels were run for approx-
imately 3 hours at 65 W and analyzed following autoradio-
graphic band detection using a STORM phosphorimager
(Molecular Dynamics, Sunnyvale, CA). AI was determined
by visual examination by two investigators as previously
reported [41] and samples that defined AI breakpoints were
verified using PCR products from a separate PCR
amplification reaction.
Statistical Analyses
Linkage was statistically evaluated using a multipoint
generalized Haseman-Elston (HE) linkage test [42] as
described previously [27]. To determine whether AI at any
marker was associated with clinical characteristics of the
men with prostate cancer (e.g., high Gleason score)
Table 2. Selected Clinical Parameters for the 48 Prostate Cancer Patients in the Study.
Patient ID Age at
Diagnosis
Prostate Cancer
Family History
PSA at
Diagnosis
Pathology
Stage
Surgical
Grade
3 -104 63 Y 5.4 T2 6
3 -130 66 N 6.0 T2 5
3 -249 51 Y 5.0 T2 6
3 -342 64 N 5.0 T3 6
4 -188 54 Y 4.6 T3 7
5 -121 55 N 5.7 T3 7
5 -187 63 Y 5.7 T3 7
5 -189 62 N 3.5 T2 6
5 -350 60 Y 6.3 T2 6
5 -369 66 N 5.6 T2 7
5 -436 63 Y 6.0 T2 6
5 -665 65 Y 6.0 T3 5
5 -905 63 N 5.4 T2 6
6 -201 64 Y 5.4 T2 5
6 -322 56 Y 5.6 T2 6
6 -350 58 N 5.6 T2 7
6 -425 61 N 6.2 T2 6
6 -452 64 Y 6.3 T3 7
7 -155 65 Y 5.5 T3 7
7 -187 63 Y 5.3 T3 7
7 -206 71 Y 5.5 T2 7
7 -220 56 Y 6.0 T2 6
7 -286 57 N 7.2 T3 7
7 -293 62 N 5.9 T2 7
7 -297 57 N 10.9 T3 6
7 -309 68 N 4.4 T2 7
7 -310 63 N 7.1 T2 7
7 -311 62 N 6.1 T2 6
7 -324 58 N 8.0 T2 5
7 -341 62 N 12.9 T3 7
7 -348 60 Y 17.0 T3 7
7 -353 56 N 5.9 T2 7
7 -375 57 N 4.8 T2 6
7 -392 60 N 13.0 T2 9
7 -393 58 N 3.4 T2 7
7 -401 59 N 25.0 T3 7
7 -404 60 Y 8.0 T2 7
7 -410 73 N 5.0 T2 6
7 -433 66 N 9.8 T3 7
7 -441 69 N 10.0 T3 8
7 -451 68 N 5.3 T2 7
7 -475 55 Y 6.6 T2 6
7 -484 62 N 8.2 T2 7
7 -485 63 N 7.6 T2 7
7 -491 63 Y 4.3 T2 7
7 -684 48 Y 5.9 T2 7
7 -923 71 Y 5.0 T3 7
8 -501 47 N 18.2 T3 9
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Fischer’s exact 2 test was used. Analyses were carried
out using the statistical software SAS (SAS Institute,
Cary, NC).
Results
Radiation Hybrid Mapping of 7q Microsatellite Markers
To confirm the order of the 11 microsatellite markers used
in this study, the low-resolution GB4 radiation hybrid panel
[39] was used. We found the mapping order of the markers
to be in agreement with that given for the Marshfield linkage
map with the exception of marker D7S640, which our data
places distal to D7S2452, and marker D7S495, which lies
distal to D7S684 according to our study. The chromosomal
order of these markers, as determined by analysis with Map
Manager QT is shown in Table 1.
Linkage Analysis
Incorporating the data from the five additional markers
into our original linkage analysis strengthened evidence of
linkage (Figure 1 ). We observed a broad region of linkage for
which P<.005 between markers D7S3061 and D7S495.
Within this region, a 6-cM peak (P<.001) encompassing
markers D7S2452 and D7S640 was identified, supporting
the presence of a gene involved in the development of
aggressive forms of prostate cancer on 7q32–q33.
AI at 7q32–q33
Overall, 38 of the 48 (79%) samples studied showed AI
with at least one marker. The AI frequencies for each marker
are shown in Table 3. The highest frequencies of AI were
exhibited by adjacent markers D7S2531 (52%) and
D7S1804 (36%). Twenty-seven of the 48 samples studied
displayed AI involving D7S2531 and/or D7S1804, with 24
tumors showing interstitial deletions across this region
(Figure 2 ). Representative autoradiographs for four of the
samples showing interstitial AI across D7S2531/D7S1804
are shown in Figure 3.
Clinical Associations
We examined any potential clinical associations bet-
ween tumors showing interstitial AI involving D78S2531
and/or D7S1804 compared with 21 samples that showed
no AI at either marker. This analysis was designed to
remove any bias from surrounding unrelated AI. Parame-
ters such as family history (self - reported and defined as
having at least one first -degree affected relative), PSA at
diagnosis, Gleason score, and tumor stage were studied
(Table 2). A statistically significant association (P=.03)
was seen between early age at diagnosis ( <60 years of
age) and interstitial AI at marker D7S1804. A weaker, but
still noteworthy, association was observed between inter-
stitial AI involving D7S1804 and a high combined Gleason
score (>7) and tumor stage (T2c) (P=.06). An
association between AI with marker D7S2531 and positive
Table 3. AI on Chromosome 7q31–q35 Loci in 48 Primary Prostate Tumors.
Marker Name AI/Informative
(% of AI)
Cytogenetic
Location*
D7S3061 CHCL.GGAA6D03 12/43 (28%) 7q31.32
D7S1875 AFMa345wc9 5/30 (17%) 7q31.33
D7S530 AFM249f9 4/42 (10%) 7q32.1
D7S2519 AFMc024we9 7/35 (20%) 7q32.2
D7S2531 AFM338wd5 16/31 (52%) 7q32.2
D7S1804 CHCL.GATA43C11 12/33 (36%) 7q33
D7S2452 AFMa282wf9 7/39 (18%) 7q33
D7S640 sWSS1204 6/37 (16%) 7q33
D7S684 AFM312wb5 9/42 (21%) 7q34
D7S495 AFM168c3 6/25 (24%) 7q34
D7S1824 CHLC.GATA32C12 8/41 (20%) 7q35
*According to the NCBI Entrez Genome web site
(http://www.ncbi.nlm.nih.gov).
Figure 1. Results from linkage analysis of prostate cancer aggressiveness on
chromosome 7. Broken lines indicate results from the original analysis; solid
line denotes results from new analysis. Values on the x - axis show marker
positions according to Marshfield Medical Research Foundation, Human
Genetics web site and our radiation hybrid mapping data.
Figure 2. Summary of 24 primary prostate tumor samples showing interstitial
AI on 7q involving D7S2531 and D7S1804. Markers are listed on the left;
sample numbers are shown across the top. (5 ) Informative samples with no
AI; (& ) informative samples demonstrating AI; (6 ) noninformative (homo-
zygous ) samples; ( — ) did not work. Boxes define maximum extent of AI for
each sample.
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family history for prostate cancer (P=.05) was also
observed.
Discussion
The first aim of this project was to provide further evidence
for a prostate cancer tumor aggressiveness locus on
chromosome 7q32–q33. In our original genome-wide multi-
point linkage study [27] we found three microsatellite
markers that defined linkage to Gleason score (P<.01)
across 7q31–q35 covering a 28 cM region. The linkage
region with P<.0001 spanned approximately 8 cM and
included the marker D7S1804. In the present study, we
undertook finer -scale genotyping in this region using five
additional markers (D7S530, D7S2452, D7S640, D7S684,
and D7S495) with the same sibling population used in the
original study. We found that linkage was maintained on
chromosome 7q32–q33, when data were analyzed with
respect to Gleason score (Figure 1 ) and strengthened
(P<.005) across the 28 cM region. Furthermore, the highest
linkage peak was reduced in size to approximately 6 cM
(P<.001) between markers D7S2452 and D7S684. These
data imply that this region harbors a gene involved in
increased risk for developing more aggressive forms of
prostate cancer.
Hereditary chordoma was recently mapped to this region
on chromosome 7q32–q33 [43]. Chordomas are rare,
locally invasive primary tumors of the bone believed to
develop from notochordal remnants. Although these tumors
are slow growing, they frequently recur following surgery or
radiotherapy [44], implying some aggressive biologic behav-
ior. Three families affected by chordoma showed linkage
between markers D7S512 and D7S684, which span the
region observed in the present study [43]. Furthermore,
another form of familial chordoma has been mapped to 1p36
[45], also reported as a prostate cancer susceptibility locus
CAPB [3 ]. Although there is a moderate male predominance
(1.7:1) for this disease [43], there are no reports of an
association with prostate cancer. Reported analysis of four
chordoma tumor samples from affected family members did
not reveal any LOH suggesting that this gene and the
prostate cancer aggressiveness gene may not be the same
[43] or do not undergo the same forms of gene inactivation.
However, additional studies would be needed to determine
this.
A second goal of the study was to provide evidence of a
tumor suppressor gene in this region by applying AI analyses
to 48 prostate tumors from patients unselected for family
history or clinical status of disease. These studies demon-
strated a high frequency of AI within this region. Overall, 79%
(38 of 48) of the tumors showed AI of at least one marker.
The highest frequency of AI was found at markers D7S2531
(52%) and D7S1804 (36%). Furthermore, 24 tumors (50%)
showed interstitial AI involving D7S2531 and/or D7S1804
(Figure 2 ) and defined a common region of deletion between
these two markers of approximately 1.1 Mb in size, based
on build 28 of the public genome sequencing database at
NCBI. This pattern of interstitial AI also suggests that the
region we have defined in this study is distinct from that
containing the ST7 candidate tumor suppressor gene on
7q31.3 (Figure 4 ).
The common fragile site FRA7H maps between markers
D7S2519 and D7S2531 [46,47]. Fragile sites are regions of
the genome particularly prone to breakage and often are
associated with regions of AI. Several candidate tumor
suppressor genes have been mapped to fragile sites
including FHIT on 3p14.2 (FRA3B) [48], the multiple
candidate tumor suppressor ST7 on 7q31 (FRA7G)
[38,49] and the putative prostate cancer susceptibility locus
at 16q23 (FRA16D) [16,50,51].
We also investigated any clinical associations with
occurrence of AI at markers D7S2531 and D7S1804 by
comparing tumors with interstitial AI at D7S2531 and/or
D7S1804 and those without AI at either marker. A statisti-
cally significant association (P=.05) was observed between
AI at D7S2531 and positive family history. AI at D7S1804
was associated with early age at diagnosis (P=.03) and a
high combined Gleason score and tumor stage (P=.06). A
similar trend was seen when Gleason score (P=.14) or
tumor stage (P=.16) were analyzed separately. These data
strongly suggest that this region contains a gene associated
with prostate tumor aggressiveness that is implicated in the
Figure 4. Schematic representation of 7q32–q33 region showing positions of
linked region, AI, fragile site and ST7 tumor suppressor gene. Not shown to
scale. ST7=supression of tumorigenicity 7 gene; FRA7H= fragile site 7H;
AI=common region of allelic imbalance.
Figure 3. Examples of autoradiographs from AI studies on matched normal
(N ) and prostate tumor (T ) pairs. Samples 7–286 and 7–393 both exhibit AI
at markers D7S2531 and D7S1804 but retain D7S2519 and D7S2452. Tumor
7–220 shows AI at D7S2531 but no AI at any neighboring marker. Sample
7–310 demonstrates AI at D7S1804 but not at any flanking marker. (& ) AI;
(5 ) no AI; arrows indicate AI.
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etiology of both hereditary and nonfamilial forms of prostate
cancer.
Sequence coverage of the chromosome 7q32–q33
region is almost complete with three small gaps in the NCBI
database. The region contains relatively few transcripts, but
contains some intriguing candidates for a prostate cancer
tumor aggressiveness gene, including two known genes,
muskelin-1 (MKLN1 ) [52] and podocalyxin- like protein
(PODXL ), and four hypothetical genes, KIAA1550,
LOC91583, LOC91584 (similar to mouse plexin 3), and
LOC96016 (similar to Eukaryotic Translation Elongation
Factor 1 Beta 2).
Muskelin-1 is a novel intracellular protein that acts as a
positive mediator of cell -spreading, adhesion, and cytoske-
letal responses to the extracellular matrix component
thrombospondin-1 (TSP-1) [53]. TSP-1 is a potent
antiangiogenic molecule [54] and has been shown to inhibit
tumor growth and metastasis [55]. TSP-1 is upregulated by
p53 and depleted in primary prostate tumors that express
mutant p53 [56]. Evidence suggests that muskelin (MKLN1)
is required for cellular responses to TSP-1 [53], implying a
role for this protein in the regulation of the biologic
aggressiveness of tumors.
Podocalyxin- like protein is a transmembrane sialomucin
involved in adhesion in renal glomerular podocytes and
vascular endothelium [57]. PODXL was recently shown to
be identical to the testicular germ cell tumor marker, gp200,
which is associated with highly malignant tumors [58].
Several regions of homology to both mouse and human
plexins are identified within the hypothetical genes including
PSI (domain found in plexins, semaphorins, and integrins)
and IPT ( immunoglobulin- like fold shared by plexins and
transcription factors) domains common to the plexin family of
proteins [59]. Plexins have been reported to act as cell
surface receptors for semaphorins [60], and are implicated
in axon repulsion, angiogenesis regulation, and tumor
growth and metastasis [61]. The PSI domain found within
the extracellular regions of both plexins and semaphorins
shows homology to part of the oncoprotein MET. MET and
other scatter factor receptors have been shown to play a role
in cell motility and invasion [62].
To provide evidence of a role in prostate tumor aggres-
siveness, we are currently performing germline mutation
analyses of candidate genes in men with prostate cancer that
show linkage to this region. In addition, we hope to identify
more linked families for which there is tumor tissue available
and perform AI studies to further confirm and narrow this
region.
In summary, we have further refined a region of linkage
on chromosome 7q32–q33 associated with prostate cancer
tumor aggressiveness. We have also demonstrated a high
frequency of AI within this region and have mapped the
smallest region of AI to approximately 1.1 Mb between
markers D7S2531 and D7S1804. Furthermore, we found
that AI at marker D7S1804 was associated with early age of
onset of prostate cancer and high combined Gleason
score/ tumor stage and that marker D7S2531 was asso-
ciated with family history of prostate cancer in an unselected
series of prostate cancer patients. These data support the
mapping of a gene to 7q32–q33 associated with aggressive
forms of both familial and nonfamilial prostate cancer.
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